Recent commercial success belies conventional wisdom that vaccines are a low-margin, moribund sector. But will the trend continue? Cormac Sheridan investigates.
This is a preview of subscription content, log in via an institution to check access.
References
Patel, H. & Makarova, A. Emerging Vaccines (Decision Resources Waltham, Massachusetts, December 2008).
Giuliani, M.M. et al. Proc. Nat. Acad. Sci. USA 103, 10834–10839 (2006).
Pass, R.F. et al. NEJM 360, 1191–1199 (2009).
Reap, E.A. et al. Vaccine 25, 7441–7449 (2007).
Wloch, M.K. et al. J. Infect. Dis. 15, 1634–1642 (2008).
Kuklin, N.A. et al. Infect. Immun. 74, 2215–2223 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Vaccine market boosters. Nat Biotechnol 27, 499–501 (2009). https://doi.org/10.1038/nbt0609-499
Issue Date:
DOI: https://doi.org/10.1038/nbt0609-499
- Springer Nature America, Inc.
This article is cited by
-
Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market
Applied Microbiology and Biotechnology (2010)